Body Dysmorphic Disorder

Special concerns about body appearance

Body dysmorphic disorder is a subtype of obsessive-compulsive disorder but often much more impairing, and also a somatoform disorder, having physical symptoms that are suggestive of a somatic disorder but with no detectible organic or neurological explanation. It is defined in the American Psychiatric Association's DSM-IV (code 300.7) with the following criteria:

  1. Preoccupation with an imagined defect in appearance. If a slight physical anomaly is present, the person's concern is markedly excessive.
  2. The preoccupation causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
  3. The preoccupation is not better accounted for by another mental disorder (for example, dissatisfaction with body shape and size in Anorexia Nervosa).

BDD has a high comorbidity rate with many other disorders including major depression, avoidant personality disorder, obsessive-compulsive disorder, delusional disorder, and social phobia. Other symptoms of the disorder may include binge-eating.

Differential diagnosis

Other conditions that may be confused with BDD include

BDD in men

Treatment

Dr. Gorbis' Crooked Mirrors Externalization therapy is a ground-breaking protocol that utilizes both Externalization techniques and Exposure and Response Prevention. The process of 'externalization' works by causing the breakdown of maladaptive associations directed and repetitive manipulation of their external, material icons. In exposure therapy, BDD patients are provided with a symptoms list and must then induce the debilitating condition and self-monitor/rate objective signs, such as pulse rate, extent of nausea, dizziness, and cognitive distortions e.g. 'My nose and forehead are too big.' Cognitive restructuring through writing exercises and observational records are emphasized.

Our success rate with this combined therapy is thus far is as follows: a 74.19% reduction of BDD-YBOCS scores, 67.97% reduction of YBOCS scores, 77.7% reduction of OCI-SV, 73.23% of OCON1 and 70.04% reduction of OCON2.

Source: Page 507, DSM-IV, 2005, American Psychiatric Association

Announcements & Upcoming Events

LACPA 2012 Brown Bag Lecture January 9, 2012 LACPA Office

Dr. Gorbis will be lecturing on the "Comorbidity of OCD and Eating Disorders and its Implication to Treatment" to members of the LA County Psychological Association. She will be addressing the issue of comorbidity of OCD and eating disorders and the implications of each disorders in terms of etiology as well as treatment.

Medical research study of an investigational medicine for patients with OCD who have not responded to treatment with SSRIs

To pre-qualify for this study, patients must be at least 18 yrs. old, have a documented diagnosis of OCD as defined by the DSM-IV-TR, have been taking one of the following SSRIs for at least six weeks prior to screening and at the minimum daily dosage listed: fuvoxamine (Luvox®) 200 mg, fluoxetine (Prozac®) 40 mg, paroxetine (Paxil®) 40 mg, sertraline (Zoloft®) 100 mg. The study is expected to last about 20 weeks. Each patient will receive study medication and study-related medical evaluations at no cost. Reimbursement for travel may also be provided. Please contact us for additional eligibility requirements.

[Admin: Update]